Exelixis EXEL Japan — Total revenues
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exelixis's japan — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exelixis's japan — total revenues?
- Exelixis (EXEL) reported japan — total revenues of $12.7M in Q1 2026.
- How has Exelixis's japan — total revenues changed year-over-year?
- Exelixis's japan — total revenues increased by 128.5% year-over-year, from $5.56M to $12.7M.
- What is the long-term trend for Exelixis's japan — total revenues?
- Over 4 years (2021 to 2025), Exelixis's japan — total revenues has grown at a -12.4% compound annual growth rate (CAGR), from $43.5M to $25.59M.
- What does japan — total revenues mean?
- The total amount of money earned from sales and licensing activities in the Japan market.
- How do you interpret japan — total revenues?
- An increase suggests successful market adoption and growth of the company's oncology products in Japan, while a decrease may indicate competitive pressure, regulatory hurdles, or changes in pricing and reimbursement environments.
- How does japan — total revenues compare across companies?
- Comparable to regional revenue reporting for other biopharmaceutical companies, often benchmarked against local market growth rates and the performance of specific oncology therapeutic classes in the Japanese healthcare system.